Clinical trials: Metastatic Malignant Neoplasm to Brain
Brain Metastases, Chemotherapy
HFSRT With Concurrent TMZ for Large BMs
A multi-center randomized phase III trial was conducted to investigate the feasibility and safety of adding temozolomide to hypofractionated stereotactic radiotherapy for large brain metastases.
- Conditions
- Brain Metastases, Chemotherapy, Radiotherapy
- Trial name
- NCT03778541
- Testing
- Temozolomide, hypofractionated radiotherapy
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Chinese Academy of Medical Sciences
Metastatic Melanoma, Brain Metastases
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
1.1. Primary Objectives 1. To determine if nab-paclitaxel and temozolomide can be combined with full dose of bevacizumab for the therapy of patients with newly diagnosed brain metastases of metastatic malignant melanoma.
- Trial name
- NCT02065466
- Testing
- nab-paclitaxel, Temozolomide, Bevacizumab
- Where
- 2 sites in United States
- Sponsor
- University of Arizona
Brain Metastases
Phase 1 Trial for Tumor Treating Field for Drug/Radiation Resistant Brain Metastases
Brain metastasis is a very common disease with poor prognosis, 20% cancer will develop brain metastases(BM), up to 40% by autopsy.
- Trial name
- NCT04967027
- Testing
- ASCLU-300 TTF
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Xiangya Hospital of Central South University
Non-small Cell Lung Cancer
Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)
RATIONALE: Radiation therapy to the brain may be effective in preventing brain metastases in patients with advanced non-small cell lung cancer.
- Trial name
- NCT01158170
- Testing
- Prophylactic cranial irradiation, Erlotinib /Gefitinib
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Zhejiang Cancer Hospital
Brain Metastases, Adult, Stereotactic Radiotherapy
a Feasibility Study of iHD-SRT for BM
Brain metastasis is the most challenging disease in the field of tumor treatment, with a median overall survival of only 1-2 months for untreated patients.
- Trial name
- NCT06231186
- Testing
- iHD-SRT
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Ruijin Hospital
Brain Metastases From HER2 and Breast Cancer, Advanced HER2-positive Breast Cancer
ARRY-380 + Trastuzuamab for Breast w/ Brain Mets
The purpose of this study is to test the safety of different doses of ARRY-380 in combination with trastuzumab. Trastuzumab is an FDA approved drug for the treatment of HER2 metastatic breast cancer.
- Trial name
- NCT01921335
- Testing
- ARRY-380 Twice Daily Dosage, ARRY-380 Once Daily, Trastuzumab
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
A Pilot Study of Eribulin in Breast Cancer (BC) Patients With Brain Metastases Previously Treated With Anthracyclines and Taxanes
This is a pilot study, the principal investigator plans to enroll 14 patients. If 2 or more responses are documented, the principal investigator will consider to start a new phase II study.
- Trial name
- NCT03412955
- Testing
- Eribulin Mesylate
- Where
- 2 sites in Singapore, Taiwan
- Volunteers
- 14 people
- Sponsor
- Tan Tock Seng Hospital
Brain Metastases From Solid Tumors
Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
This is an open-label, single dose, single arm, multicenter Phase 2b study to establish the imaging performance of RAD101 PET in participants who are ≥ 18 years of age and with suspected recurrent brain metastases from solid…
- Trial name
- RAD101 (NCT06777433)
- Testing
- RAD101 (18F-FPIA)
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Radiopharm Theranostics, Ltd
Brain Metastases, Adult
Fractionated Stereotactic Radiotherapy for Limited Small Volume Brain Metastases
This is a single-center, open lable, single-arm phase II clinical study to evaluate the efficacy and safety of fractionated stereotactic radiotherapy (FSRT) in patients with 1-4 brain metastases with ≤2cm in diameter.
- Trial name
- NCT07405047
- Testing
- fractionated stereotactic radiotherapy
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Brain and Central Nervous System Tumors, Metastatic Cancer
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors
RATIONALE: Photodynamic therapy uses light and photosensitizing drugs to kill tumor cells and may be an effective treatment for refractory brain tumors.
- Trial name
- NCT00002647
- Testing
- verteporfin, conventional surgery
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Medical College of Wisconsin
Small-cell Lung Cancer, Brain Metastases
7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)
Comparison of a 7t MRI to standard of care 1.5t/3t MRI scans to determine if earlier detection of brain metastases are possible on a 7t.
- Trial name
- NCT07175077
- Testing
- 7t MRI
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Missouri-Columbia
Brain Metastases, Adult Solid Tumor
Cyberknife Radiosurgery for Patients With Brain Metastases Diagnosed With Either SPACE or MPRAGE Sequence
For patients with cerebral oligometastases who are in adequate clinical condition stereotactic radiosurgery (SRS) is the treatment of choice, being recommended by international guidelines for the treatment of one to four lesions.
- Trial name
- CYBER-SPACE (NCT03303365)
- Testing
- stereotactic radiosurgery (SRS)
- Where
- Germany
- Volunteers
- 203 people
- Sponsor
- Juergen Debus
Breast Cancer Metastatic
Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients
Multicenter open-label, phase II trial, to evaluate the efficacy and safety of nal-IRI in patients with HER2-negative breast cancer, who have documented Central Nervous System (CNS) progression following Whole Brain Radio Therapy…
- Trial name
- Phenomenal (NCT03328884)
- Testing
- Irinotecan (CPT-11) liposome
- Where
- 16 sites in Spain
- Volunteers
- 55 people
- Sponsor
- MedSIR
Brain and Central Nervous System Tumors, Metastatic Cancer
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00002752
- Testing
- iodine I 131 monoclonal antibody 81C6
- Where
- United States
- Sponsor
- Duke University
Brain Metastases, Radiation Necrosis
REMASTer: REcurrent Brain Metastases After SRS Trial
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic…
- Conditions
- Brain Metastases, Radiation Necrosis, Recurrent Tumor, Recurrent Metastases
- Trial name
- NCT05124912
- Testing
- Radiation Therapy, Steroid Therapy, Laser Interstitial Thermal Therapy
- Where
- 9 sites in United States
- Volunteers
- 261 people
- Sponsor
- Monteris Medical
Non Small Cell Lung Cancer, Brain Metastases
The Role of Brain Radiotherapy in Patients With Asymptomatic Brain Metastasis in the Era of Targeted Therapy for NSCLC
Brain metastasis is the most common neurological complication in tumor patients, and lung cancer is the most common tumor with brain metastasis.
- Trial name
- BRATR (NCT04193007)
- Testing
- molecular targeted therapies, Brain Radiotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Metastatic Malignant Neoplasm in the Brain
Frameless Fractionated Stereotactic Radiation in Treating Patients With Brain Metastases
This phase II trial studies the safety and efficacy of frameless fractionated stereotactic radiation therapy for brain metastases.
- Trial name
- NCT02798029
- Testing
- Frameless Fractionated Stereotactic Radiation Therapy
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Antifungals, such as caspofungin acetate, may be effective in treating fungal infections caused by chemotherapy or stem cell transplant.
- Trial name
- NCT00110045
- Testing
- caspofungin acetate
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 171 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Melanoma
Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases
The purpose of this trial is to study the activity of vemurafenib in untreated melanoma brain metastases harboring B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutations that are not amenable to stereotactic radiosurgery…
- Trial name
- NCT01781026
- Testing
- Vemurafenib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Yale University
EGFR-TKI Resistant Mutation, Nonsmall Cell Lung Cancer
Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M
The study aims to investigate the efficacy and safety of AZD9291 in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI.
- Conditions
- EGFR-TKI Resistant Mutation, Nonsmall Cell Lung Cancer, AZD9291, Brain Metastases
- Trial name
- NCT02972333
- Testing
- AZD9291 80mg oral each day, Radiation therapy
- Volunteers
- 150 people
- Sponsor
- Shandong Cancer Hospital and Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.